Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH1 | Q13686 | 8/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875991 | 0.92 | MAPT (0.49) | ALKBH1KLKB1PPARDPPARAMAPT | |
| SCHEMBL12875981 | 0.87 | KLKB1 (0.41) | ALKBH1KLKB1MAPTTDP1L3MBTL1 | |
| SCHEMBL1198715 | 0.87 | ALDH1A1 (0.42) | ALKBH1KLKB1PPARDPPARAL3MBTL1 | |
| SCHEMBL12876129 | 0.86 | KMT2A (0.45) | ALKBH1KLKB1PPARDPPARAKMT2A | |
| SCHEMBL12875968 | 0.85 | L3MBTL1 (0.41) | ALKBH1KLKB1TDP1L3MBTL1EGLN1 | |
| SCHEMBL1198990 | 0.85 | EGLN1 (0.52) | ALKBH1PPARDPPARAEGLN1 | |
| SCHEMBL12876017 | 0.82 | MEN1 (0.41) | ALKBH1KLKB1PPARDPPARAMAPT | |
| SCHEMBL12876201 | 0.82 | KLKB1 (0.40) | KLKB1MAPTL3MBTL1KMT2A | |
| SCHEMBL2857263 | 0.81 | MAPT (0.46) | KLKB1PPARDPPARAMAPTTDP1 | |
| SCHEMBL12876294 | 0.81 | RAB9A (0.36) | ALKBH1KLKB1L3MBTL1EGLN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | ALKBH1 1916/4885KLKB1 3765/4885PPARD 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.